venetoclax + obinutuzumab + zanubrutinib

This treatment regimen is a minimal residual disease (MRD)-tailored approach for young patients (aged 18-65) with previously untreated high-risk chronic lymphocytic leukemia (CLL). Developed and studied by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) in the CLL2222 trial, the regimen utilizes a sequential and response-adapted combination of three potent agents: venetoclax (a BCL-2 inhibitor), obinutuzumab (an anti-CD20 monoclonal antibody), and zanubrutinib (a next-generation BTK inhibitor). All patients begin with venetoclax and obinutuzumab (VenObi) induction. At cycle 9, treatment is intensified with the addition of zanubrutinib (VenZan) for those with detectable residual disease, while those achieving undetectable MRD (uMRD) continue with venetoclax monotherapy. This strategy aims to optimize deep molecular responses and allow for treatment discontinuation in patients achieving uMRD.

Other names

VenObi + VenVenObi + VenZanVenObi-VenZanVenObi + Ven or VenObi + VenZan